Monoclonal anti-IL-1RAcP antibodies
Monoclonal antibody that specifically binds the interleukin 1 receptor type 1 (IL-1RAcP), or an antigen binding fragment thereof, comprising: a) a heavy chain variable region (VH) comprising CDR1H, CDR2H and/or CDR3H, wherein the CDR1H region comprises an amino acid sequence selected from the group of SEQ ID NO: 155-231, wherein the CDR2H region comprises an amino acid sequence selected from the group of SEQ ID NO: 232-308, and wherein the CDR3H region comprises an amino acid sequence selected from the group of SEQ ID NO: 309-385; and b) a light chain variable region (VL) comprising CDR1L, CDR2L and/or CDR3L, wherein the CDR1L region comprises an amino acid sequence selected from the group of SEQ ID NO: 386-462, wherein the CDRL2 region comprises an amino acid sequence selected from the group of SEQ ID NO: 463-539, and wherein the CDR3L region comprises an amino acid sequence selected from the group of SEQ ID NO: 540-616. The monoclonal antibody is characterized in that it inhibits IL-1RAcP induced NFkB activity, useful in treatment of IL-1RAcP related diseases.
1. A monoclonal antibody, or antigen binding fragment thereof, that specifically binds to IL-1RAcP, wherein the monoclonal antibody, or antigen binding fragment thereof, comprises
a VH region comprising the CDR1H region of SEQ ID NO: 214, the CDR2H region of SEQ ID NO: 291 and the CDR3H region of SEQ ID NO: 368, and a VL region comprising the CDR1L region of SEQ ID NO: 445, the CDR2L region of SEQ ID NO: 522 and the CDR3L region of SEQ ID NO: 599.
2. The monoclonal antibody, or antigen binding fragment thereof, according to claim 1 , wherein the antibody, or antigen binding fragment thereof, comprises.
3. The monoclonal antibody, or antigen binding fragment thereof, according to claim 1 , characterized in comprising at least amino acid substitutions at L234A and L235A of the human IgG1 Fc region or S228P and L235E of the human IgG4 Fc region.
4. The monoclonal antibody, or antigen binding fragment thereof, according to claim 1 , characterized in being a rabbit/human chimeric or humanized antibody.
5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to claim 1 .
6. The monoclonal antibody, or antigen binding fragment thereof, according to claim 1 , wherein the antibody, or antigen binding fragment thereof, inhibits IL-1alpha, IL-1beta, IL-33, and/or IL-36 stimulated luciferase activity in 293T/17 cells.